Arcutis Biotherapeutics ARQT 深 沪

Crude Oil Falls Over 2%; PayPal Shares Spike Higher

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...

10-29 00:18

Earnings Scheduled For October 28, 2025

Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...

10-28 19:11

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Arcutis Biotherapeutics has initiated a Phase 2 study to evaluate ZORYVE 0.05% cream in infants 3 months to under 2 years with atopic dermatitis. The four-week study will assess safety and tolerability of once-daily use, addressing limited treatment options for this age group. Atopic dermatitis affects 9.6 million children in the U.S., with up to 60% developing symptoms within the first year.

06-10 12:00

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted 72,000 restricted stock units to 9 new employees under its 2022 Inducement Plan, with a grant date of June 2, 2025. The units vest over four years.

06-06 20:00

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

New data from the INTEGUMENT-OLE study show that ZORYVE cream provides long-term improvement in atopic dermatitis symptoms, with children aged 2–5 achieving disease control for up to 238 days. The cream also demonstrated consistent safety and tolerability.

06-06 12:00

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Arcutis Biotherapeutics' management will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 9-11, 2025. A fireside chat with Arcutis management will take place on June 10, 2025, at 4:00 pm EDT. The webcast can be accessed via the company's website, with a replay available for 180 days post-conference.

05-29 20:00

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

05-22 18:12

FDA Accepts Arcutis' Supplemental New Drug Application For ZORYVE Foam For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 and Over

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025Almost half of the 9 million individuals in the United States with plaque psoriasis experience

2024-09-24 20:13

Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts

Across the recent three months, 4 analysts have shared their insights on Arcutis Biotherapeutics (NASDAQ:ARQT), expressing a variety of opinions spanning from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days an...

2024-08-28 21:00

Jefferies Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $15

Jefferies analyst Kambiz Yazdi initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces Price Target of $15.

2024-08-28 20:19